European Free-to-Air TV Platforms Endorse Intertrust ExpressPlay XCA for Broadcast Content Protection
13.9.2018 15:00:00 EEST | Business Wire | Press release
Free-to-air TV platforms Freesat and Tivù have today endorsed Intertrust’s ExpressPlay XCA™ conditional access system (CAS) at IBC.
As the inventor of Digital Rights Management (DRM) technology, Intertrust introduced ExpressPlay XCA (XCA), a modern CAS that is based on their popular open standard Marlin technology, which was originally founded by Intertrust, Panasonic, Philips, Sony, and Samsung. ExpressPlay XCA leverages hardware security in smart TV and set-top box chipsets to provide world-class content security and full CAS capabilities – including head-end integration at a fraction of the cost of a legacy CAS.
“For years, TV operators have had to manage a tricky balance between set-top box manufacturers and CAS providers to deliver premium TV, often leaving themselves at the mercy of CAS vendors. Meanwhile broadband TV providers use easy-to-integrate DRM with far less overhead,” said Talal G. Shamoon, Intertrust’s chief executive officer. “With today’s TV chipsets, smart TVs and set-top boxes, we can remove legacy problems with our Marlin DRM-based XCA while reducing costs and time-to-market, and increasing choice.”
With increasing competition from the Internet, traditional TV operators are embracing economies of scale provided by modern technology. In response to smart TV manufacturers readily integrating DRM systems into their OTT stack, Intertrust created XCA to provide broadcasters with a simple way to reduce their costs.
“As Freesat expands its connected product range, we sought a cost efficient, open alternative to traditional CAS,” said Andy Carr Director of CE @ Freesat. “XCA provides us with industry approved content security across a broad range of devices. As our service continues to grow, Intertrust becomes a key partner for us protecting the best possible high-value entertainment experience for our customers.”
To protect and manage content, XCA technology is used in TV platforms across Europe, India, China, Japan, and the United States. Its advanced DRM software engine efficiently protects broadcast streams, resulting in a future proof, open technology that is flexible and cost effective.
“Our viewers are the most important element in the equation,” said Alberto Sigismondi, Tivù chief executive officer. “With XCA, we could provide our viewers with a range of content choice across traditional TV platforms and set-top boxes, but also bridge the gap between the interests of Italy’s broadcasters.”
Intertrust also announced at IBC that Vestel, Europe’s second largest TV manufacturer will incorporate XCA into their smart TVs. Vestel joins a growing community of device makers who support Marlin-based technologies around the world.
About Intertrust
Intertrust provides trusted computing products and services to leading global corporations – from mobile, CE and IoT manufacturers, to service providers, and enterprise software platform companies. These products include the world’s leading digital rights management (DRM), software tamper resistance, and technologies to enable private data exchanges for various verticals including energy, entertainment, retail/marketing, automotive, fintech, and IoT.
Founded in 1990, Intertrust is headquartered in Silicon Valley with regional offices in London, Tokyo, Mumbai, Bangalore, Hyderabad, Beijing, Seoul, Riga, and Tallinn. The Company has a legacy of invention, and its fundamental contributions in the areas of computer security and digital trust are globally recognized. Intertrust holds hundreds of patents that are key to Internet security, trust, and privacy management components of operating systems, trusted mobile code and networked operating environments, web services, and cloud computing.
Additional information is available at intertrust.com, or follow us on Twitter or LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180913005407/en/
Contact information
Intertrust Technologies Corporation
Nishtha Sharma, +91 981-932-6284
nishthas@intertrust.com
or
Actual
Agency
Brian Regan, +1 908-399-7161
brian.regan@actual.agency
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom